Department of Origin: Integrated Healthcare Services. Approved by: Chief Medical Officer Department(s) Affected: Date approved: 01/10/17

Similar documents
01/10/17. Replaces Effective Policy Dated: Amino Acid Based Elemental Formula (AABF) 09/28/15 Reference #: MP/A003 Page: 1 of 3

PURPOSE: The intent of this policy is to provide guidelines for coverage of dental procedures under the medical benefit.

01/26/17. Replaces Effective Policy Dated: Autism Spectrum Disorders in Children: Assessment 01/19/16 and Evaluation Reference #: MP/A005 Page 1 of 4

Approved by: Integrated Health Quality Management Subcommittee Effective Date: Department of Origin: Integrated Healthcare Services.

03/14/17. II. Initial early intensive-level behavioral and developmental therapy must have both of the following: A and B

09/12/17. I. Electrical Bone Growth Stimulator (invasive, semi-invasive, or non-invasive) any of the following: A-C

06/13/17. A. Completed a comprehensive diabetes education program within the past two years; and

03/13/18. A. Symptoms lasting for greater than or equal to 12 months that have resulted to significant impairment in activities of daily living; and

FYI ONLY Generic Name. Generics available. zoledronic acid N/A

B. To assess an individual when clinical evaluation suggests use of non-prescribed medications or illegal substances; or

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 12/19/17 SECTION: MEDICINE LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Date approved: 04/18/18. Approved by: Pharmacy and Therapeutics Quality Management Subcommittee Effective Date: Department of Origin: Pharmacy

Calendar Year Deductible Annual Benefit Maximum. ADA Code Covered Services Member pays. n/a Office visit $5 per visit

Santa Clara Family Health Plan Cal MediConnect Plan (Medicare-Medicaid Plan) 2017 Drug List

Tusculum College. Benefit Summary. $25 Copay. $25 Copay. after Deductible. 20% after Deductible 20% after Deductible

GENETIC TESTING FOR PREDICTING RISK OF NONFAMILIAL BREAST CANCER

Pediatric Dental and Vision

2018 Preventive Schedule

Smile SM Value 50/1500/No Ortho/MAC

LARTRUVO (olaratumab)

DRUG TESTING IN PAIN MANAGEMENT AND SUBSTANCE USE DISORDER(S) TREATMENT

Calendar Year Deductible Annual Benefit Maximum. ADA Code Covered Services Member pays

IMMUNE CELL FUNCTION ASSAY

Smile SM Deluxe Gold 50/1500/Ortho/U85

Approval of a drug under this criteria document does not ensure full coverage of the drug.

Tusculum College. Benefit Summary Option/Quote: 2. 30% after Deductible. $35 Copay. 30% after Deductible

GENETIC TESTING FOR TAMOXIFEN TREATMENT

ENDOBRONCHIAL ULTRASOUND FOR DIAGNOSIS AND STAGING OF LUNG CANCER

12/13/16. I. Liver transplantation for children and adults (initial or retransplantation) - must satisfy the following: A and B

06/12/18. [Note: When orthognathic surgery is not a covered benefit, it is non-covered for any diagnosis, including sleep apnea.]

Smile SM Plus 50/1500/Ortho/MAC

HEMATOPOIETIC CELL TRANSPLANTATION FOR EPITHELIAL OVARIAN CARCINOMA

2017 Preventive Schedule

GENETIC TESTING FOR KRAS, NRAS AND BRAF VARIANT ANALYSIS IN METASTATIC COLORECTAL CANCER

12/12/17. I. Liver transplantation for children and adults (initial or retransplantation) - must satisfy the following: A and B

Dental Options 2018 BALTIMORE CITY PUBLIC SCHOOLS

PANCREATIC ISLET TRANSPLANT

Approved by: Integrated Health Quality Management Subcommittee Effective Date: Department of Origin: Integrated Healthcare Services.

$250 (Deductible does not apply to Tier 1 and Tier 2) $500 (Deductible does not apply to Tier 1 and Tier 2)

NUTRIENT OR NUTRITIONAL PANEL TESTING

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 10/04/17 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

TREATMENTS FOR GAUCHER DISEASE

RADIOFREQUENCY ABLATION OF PRIMARY OR METASTATIC LIVER TUMORS

BRINEURA (cerliponase alfa)

03/13/18. PURPOSE: The intent of this criteria document is to ensure services are medically necessary.

NOVEL BIOMARKERS IN RISK ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR DISEASE

MOLECULAR TESTING IN THE MANAGEMENT OF PULMONARY NODULES

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

ORAL IMPLANT PROCEDURES

ALPHA1-PROTEINASE INHIBITORS

FECAL ANALYSIS IN THE DIAGNOSIS OF INTESTINAL DYSBIOSIS

PARSABIV (etelcalcetide)

GENETIC TESTING FOR HEREDITARY HEARING LOSS

APOKYN (apomorphine hydrochloride)

INTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION

BLINCYTO (blinatumomab)

RADIOFREQUENCY ABLATION OF MISCELLANEOUS SOLID TUMORS EXCLUDING LIVER TUMORS

RELISTOR (methylnaltrexone bromide) INJECTION FOR SUBCUTANEOUS USE

MYLOTARG (gemtuzumab ozogamicin)

GENETIC TESTING FOR FANCONI ANEMIA

CONTINUOUS OR INTERMITTENT GLUCOSE MONITORING IN INTERSTITIAL FLUID

INTRAVITREAL IMPLANTS

PROTEOMIC TESTING FOR SYSTEMIC THERAPY IN NON-SMALL-CELL LUNG CANCER

CIMZIA (certolizumab pegol)

2018 Hearing Aids. Apply your benefit and receive two digital Level I hearing aids with $0 copay!

GENETIC TESTING FOR MARFAN SYNDROME, THORACIC AORTIC ANEURYSMS AND DISSECTIONS AND RELATED DISORDERS

NEGATIVE PRESSURE WOUND THERAPY

TYMLOS (abaloparatide)

ENTYVIO (vedolizumab)

HEMATOPOIETIC CELL TRANSPLANTATION FOR PRIMARY AMYLOIDOSIS

Ready. Set. CAPTURE LIFE REWARDS. Earn plenty of Points. GET ACTIVE ENJOY LIVE HEALTHY REWARDS GCHJMJXEN 0916

CARDIOVASCULAR RISK PANELS

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

GENETIC TESTING FOR NEUROFIBROMATOSIS

INTRACAVITARY BALLOON BRACHYTHERAPY FOR MALIGNANT AND METASTATIC BRAIN TUMORS

STRENSIQ (asfotase alfa)

STELARA (ustekinumab)

ELECTROMYOGRAPHY (EMG) AND NERVE CONDUCTION STUDIES (NCS)

MULTIMARKER SERUM TESTING RELATED TO OVARIAN CANCER

GENETIC TESTING FOR FLT3, NPM1 AND CEBPA VARIANTS IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA

PERJETA (pertuzumab) FOR TREATMENT OF MALIGNANCIES

GENETIC TESTING WITH MOLECULAR PANEL TESTING OF CANCERS TO IDENTIFY TARGETED THERAPIES

DEEP BRAIN STIMULATION

2018 Preventive Schedule Effective 1/1/2018

2017 Preventive Schedule

GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME BRCA1 BRCA2

GATTEX (teduglutide [rdna origin])

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

BONIVA (ibandronate sodium)

BALLOON OSTIAL DILATION FOR TREATMENT OF CHRONIC SINUSITIS

GENE EXPRESSION PROFILING AND PROTEIN BIOMARKERS FOR PROSTATE CANCER MANAGEMENT

OPTICAL COHERENCE TOMOGRAPHY (OCT) OF THE MIDDLE EAR

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

INTERSPINOUS FIXATION (FUSION) DEVICES

SOMATULINE DEPOT (lanreotide acetate)

Original Effective Date: 9/10/09

DERMATOLOGIC APPLICATIONS OF PHOTODYNAMIC THERAPY

AUTOLOGOUS CHONDROCYTE IMPLANTATION FOR FOCAL ARTICULAR CARTILAGE LESIONS

Transcription:

Reference #: MP/D005 Page: 1 of 3 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community Health Plan (PCHP) PreferredOne Insurance Company (PIC) Individual PreferredOne Insurance Company (PIC) Large Group PreferredOne Insurance Company (PIC) Small Group Please refer to the member s benefit document for specific information. To the extent there is any inconsistency between this policy and the terms of the member s benefit plan or certificate of coverage, the terms of the member s benefit plan document will govern. Benefits must be available for health care services. Health care services must be ordered by a physician, physician assistant, or nurse practitioner. Health care services must be medically necessary, applicable conservative treatments must have been tried, and the most cost-effective alternative must be requested for coverage consideration. This policy applies to PAS members only when the employer group has elected to provide benefits for the service/procedure/device. Check benefits in SPD/COC. If benefits not specifically addressed in the SPD/COC verify with the appropriate account manager the availability of benefits. PURPOSE: The intent of this policy is to provide guidelines for coverage of dietary formulas, electrolyte substances or food products needed to sustain life for phenylketonuria (PKU) or other inborn errors of metabolism. POLICY: Coverage of dietary formulas, electrolyte substances or food products for PKU or other inborn errors of metabolism is subject to the benefits, limitations, and exclusions in the member s benefit plan and the guidelines below. GUIDELINES: Must meet: I and any of II-IV, as applicable I. The dietary formula, electrolyte substance or food product must be ordered or prescribed by a physician, physician assistant, or nurse practitioner; and II. PAS: Check coverage under the DME schedule of benefits III. PCHP A. For members age 5 (five) years or younger, limited coverage is provided for special dietary formulas, electrolyte substances and other specialty food products that are consumed orally and treat PKU or other inborn errors of metabolism; or B. For members age 6 (six) years or older, limited coverage is provided for special dietary formulas, electrolyte substances and other specialty food products that are consumed orally and treat PKU or other

Reference #: MP/D005 Page: 2 of 3 inborn errors of metabolism when medical documentation establishes they are medically necessary and that the member is not able to sustain good with without such dietary item(s). IV. PIC A. Individual - Limited coverage for special dietary formulas and electrolyte substances that are consumed B. Large Group - Limited coverage for special dietary formulas and electrolyte substances that are consumed C. Small Group - Limited coverage for special dietary formulas and electrolyte substances that are consumed EXCLUSIONS: I. Other products that can be purchased without a prescription and other grocery items that can be prepared in a blender including food thickener, supplements, sport shakes, baby food, and related supplies. II. Specialty infant formulas for diagnosis other than inborn errors in metabolism. III. Products purchased on the internet or OTC without a prescription. DEFINITIONS: Inborn Errors of Metabolism: Comprise a large class of genetic diseases involving disorders of metabolism. The majority are due to defects of single genes that code for enzymes that facilitate conversion of various substances (substrates) into others (products). In most of the disorders, problems arise due to accumulation of substances which are toxic or interfere with normal function, or to the effects of reduced ability to synthesize essential compounds. Inborn errors of metabolism are now often referred to as congenital metabolic diseases or inherited metabolic diseases, and these terms are considered synonymous. Traditionally the inherited metabolic diseases were categorized as disorders of carbohydrate metabolism, amino acid metabolism, organic acid metabolism, or lysosomal storage diseases. In recent decades, hundreds of new inherited disorders of metabolism have been discovered and the categories have proliferated.

Reference #: MP/D005 Page: 3 of 3 FOR INTERNAL USE ONLY COVERAGE: Prior Authorization: Yes when administered orally Coverage is subject to the member s contract benefits. CODING: HCPCS B4157 Enteral formula, nutritionally complete, for special metabolic needs for inherited disease of metabolism, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories=1 unit B4162 Enteral formula, for pediatrics, for special metabolic needs for inherited disease of metabolism, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories=1 unit S9434 Modified solid food supplements for inborn errors of metabolism S9435 Medical foods for inborn errors of metabolism RELATED CRITERIA/POLICIES: Process Manual UR015 Use of Medical Policy and Criteria Medical Policy MP/C009 Coverage Determination Guidelines Medical Policy MP/A003 Amino Acid Based Elemental Formulas REFERENCES: 1. State Mandate: Minnesota Statutes 62A.26 Coverage for Phenylketonuria Treatment DOCUMENT HISTORY: Created Date: 09/14/10 (previously addressed under MP/E004) Reviewed Date: 08/31/11, 09/07/12, 09/06/13, 09/05/14, 09/04/15, 09/02/16 Revised Date: 09/07/11, 11/13/13, 04/20/15,

PreferredOne Community Health Plan Nondiscrimination Notice PreferredOne Community Health Plan ( PCHP ) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. PCHP does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex. PCHP: Provides free aids and services to people with disabilities to communicate effectively with us, such as: Qualified sign language interpreters Written information in other formats (large print, audio, accessible electronic formats, other formats) Provides free language services to people whose primary language is not English, such as: Qualified interpreters Information written in other languages If you need these services, contact a Grievance Specialist. If you believe that PCHP has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Grievance Specialist PreferredOne Community Health Plan PO Box 59052 Minneapolis, MN 55459-0052 Phone: 1.800.940.5049 (TTY: 763.847.4013) Fax: 763.847.4010 customerservice@preferredone.com You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, a Grievance Specialist is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C. 20201 1-800-368-1019, 800-537-7697 (TDD) Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html. Language Assistance Services NDR PCHP LV (10/16)

PreferredOne Insurance Company Nondiscrimination Notice PreferredOne Insurance Company ( PIC ) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. PIC does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex. PIC: Provides free aids and services to people with disabilities to communicate effectively with us, such as: Qualified sign language interpreters Written information in other formats (large print, audio, accessible electronic formats, other formats) Provides free language services to people whose primary language is not English, such as: Qualified interpreters Information written in other languages If you need these services, contact a Grievance Specialist. If you believe that PIC has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Grievance Specialist PreferredOne Insurance Company PO Box 59212 Minneapolis, MN 55459-0212 Phone: 1.800.940.5049 (TTY: 763.847.4013) Fax: 763.847.4010 customerservice@preferredone.com You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, a Grievance Specialist is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C. 20201 1-800-368-1019, 800-537-7697 (TDD) Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html. Language Assistance Services NDR PIC LV (10/16)